Roche Launches VENTANA BAP1 Test for Mesothelioma Diagnosis
Roche announced the global launch of its VENTANA BAP1 (SP527) test, an automated immunohistochemistry test for differential diagnosis of mesothelioma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
6 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Roche Launches Test for Differential Diagnosis of Mesothelioma
Roche Launches Global BAP1 Test for Mesothelioma Diagnosis
Roche launched the VENTANA BAP1 (SP527) IHC assay for differential diagnosis of mesothelioma. The assay is registered as a Class I IVD with the FDA and IVDR Class C and is available globally.
Roche Launches Mesothelioma Differential Diagnosis Test
Roche launched a test for the differential diagnosis of mesothelioma.
Roche Launches Test to Help Diagnose Mesothelioma
Roche launched a test for the differential diagnosis of mesothelioma.
Roche Launches Test to Differentiate Mesothelioma
Roche launched a test for the differential diagnosis of mesothelioma.